CD7 Targeted AAV Expands Immune Cell Engineering

Company Nanjing University (academic) Event Type Peer-reviewed publication (Nature Biotechnology) Modality Engineered AAV capsid for T and NK cell gene delivery Asset AAV.APR31 Target CD7; AAVR (cell entry) Disease Area Hematologic and solid tumors (mouse models) Summary A Nature Biotechnology paper reports an evolved AAV…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *